INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Other Events
Item 8.01 Other Events
that West-Ward Pharmaceuticals International Limited (WWPIL), a
wholly-owned subsidiary of Hikma Pharmaceuticals PLC (Hikma)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), will provide the
Company with the rights to launch our branded, fluticasone
propionate nasal spray USP, 50 mcg per spray (FlutiCare), under
WWPILs FDA approved abbreviated new drug application (ANDA) No.
207957 in the United States in the second half of 2017.
FlutiCare product. The first, originally announced in connection
with the Companys acquisition of Novalere FP, Inc. in 2015, is
pending FDA approval of the ANDA in the U.S. As a result of the
acquisition, Innovus Pharma owns worldwide rights outside of the
U.S. to this dossier and filing and intends to commercialize
FlutiCare through the use of its rights to the U.S. dossier for
the product.
this Current Report on Form 8-K.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press release issued May 9, 2017.
|
About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe. INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Recent Trading Information
INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) closed its last trading session down -0.006 at 0.100 with 490,868 shares trading hands.